Fritextsökning
Innehållstyper
-
TECHNIA AB
-
Cytel Sweden
-
Webinar: Support Trial Patients Transitioning to the Commercial Space
Register for expert insights on supporting Phase III clinical trial patients post-approval and read our blog on advanced Patient Assistance Programs.
-
Mastering Urine Microscopy
On-demand Webinar: Microscopy in urinalysis.
-
Zelmic
-
A+ Science AB
-
Meribel Pharma Solna
-
KI-studie: Nässköljning kunde ge information om KOL
Förekomsten av ett visst protein i näsan kunde användas som underlag för bedömning av KOL, i en ny studie från forskare vid Karolinska institutet.
-
Metabolon
-
Fast Optical Sectioning of Developing Organisms and Tissue Microstructures
ZEISS Lattice SIM 3 exploits the full potential of the SIM Apotome technology.
-
RegFile AB
-
Advancing Drug Discovery by Combining Complex In-Vitro Models with AI-Powered 3D/4D Image Analysis
Free webinar organized by ZEISS.
-
Drug development booms in Medicon Valley
When it comes to developing new medicines, the Öresund region is one of the top performers in the EU. Companies working on commission for pharmaceutical compani...
-
Orbán's extended arm becomes health commissioner in the EU
Hungarian Olivér Várhelyi may soon become the most influential official for the healthcare and pharmaceutical industry in the EU. Várhelyi, who is close to Hung...
-
Sahlgrenska Science Park
-
LINK Medical Research
-
In search of Marcel Proust's lost health
A great writer, but also a weak person and a hypochondriac. That has been the usual image of Marcel Proust. But the pediatrician and literary scholar Carl Lindg...
-
The new Swedish life science strategy – “It will consolidate Sweden as a leader”
Clinical trials and precision health are emphasised as key areas in the new national life science strategy.
-
Kompauto Nordic AB
-
Merck Life Science A/S
-
Medicon Village Science Park
-
Bio-Works
-
Are you curious about volume imaging for very large samples?
Exciting ZEISS Webinar!
-
AZ gets approval for drug targeting rare disease – it may reduce cortisone dependence
AstraZeneca’s drug Fasenra gets an expanded indication in the EU and is now approved as a treatment for the rare autoimmune disease known as Churg-Strauss syndrome.